Hyunki Kim1,2, Yolanda E Hartman3, Guihua Zhai1, Thomas K Chung3, Melissa L Korb3, Timothy M Beasley4, Tong Zhou5, Eben L Rosenthal2,3. 1. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. 3. Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA. 4. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA. 5. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
PURPOSE: To assess the early therapeutic effects of anti-EMMPRIN (extracellular matrix metalloprotease inducer) antibody with/without cisplatin or X-ray radiation in head and neck cancer mouse models using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). MATERIALS AND METHODS: Mice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n = 4-5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and K(trans) values were averaged in a 0.5-mm-thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging. RESULTS: The K(trans) changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were -18 ± 8% and 4 ± 7%, respectively, which were significantly lower than those of control groups (39 ± 5% and 45 ± 7%; P = 0.0025 and 0.0220, respectively). When cisplatin was added, those were -42 ± 9% and -44 ± 9%, respectively, and with radiation, -45 ± 9% and -27 ± 10%, respectively, which were also significantly lower than those of control groups (P < 0.0001 for all four comparisons). In the eight groups untreated (served as control) or treated with anti-EMMPRIN antibody with/without cisplatin or radiation, the mean K(trans) change for 3 days was significantly correlated with the mean tumor volume change for 7 days (r = 0.74, P = 0.0346), Ki67-expressing cell density (r = 0.96, P = 0.0001), and CD31 density (r = 0.84, P = 0.0084). CONCLUSION: DCE-MRI might be utilized to assess the early therapeutic effects of anti-EMMPRIN antibody with/without chemotherapy or radiotherapy in head and neck cancer.
PURPOSE: To assess the early therapeutic effects of anti-EMMPRIN (extracellular matrix metalloprotease inducer) antibody with/without cisplatin or X-ray radiation in head and neck cancermouse models using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). MATERIALS AND METHODS:Mice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n = 4-5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and K(trans) values were averaged in a 0.5-mm-thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging. RESULTS: The K(trans) changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were -18 ± 8% and 4 ± 7%, respectively, which were significantly lower than those of control groups (39 ± 5% and 45 ± 7%; P = 0.0025 and 0.0220, respectively). When cisplatin was added, those were -42 ± 9% and -44 ± 9%, respectively, and with radiation, -45 ± 9% and -27 ± 10%, respectively, which were also significantly lower than those of control groups (P < 0.0001 for all four comparisons). In the eight groups untreated (served as control) or treated with anti-EMMPRIN antibody with/without cisplatin or radiation, the mean K(trans) change for 3 days was significantly correlated with the mean tumor volume change for 7 days (r = 0.74, P = 0.0346), Ki67-expressing cell density (r = 0.96, P = 0.0001), and CD31 density (r = 0.84, P = 0.0084). CONCLUSION:DCE-MRI might be utilized to assess the early therapeutic effects of anti-EMMPRIN antibody with/without chemotherapy or radiotherapy in head and neck cancer.
Authors: Thomas E Yankeelov; Jeffrey J Luci; Martin Lepage; Rui Li; Laura Debusk; P Charles Lin; Ronald R Price; John C Gore Journal: Magn Reson Imaging Date: 2005-05 Impact factor: 2.546
Authors: Thomas E Yankeelov; Greg O Cron; Christina L Addison; Julia C Wallace; Ruth C Wilkins; Bruce A Pappas; Giles E Santyr; John C Gore Journal: Magn Reson Med Date: 2007-02 Impact factor: 4.668
Authors: Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal Journal: Mol Cancer Res Date: 2011-06-10 Impact factor: 5.852
Authors: S Zucker; M Hymowitz; E E Rollo; R Mann; C E Conner; J Cao; H D Foda; D C Tompkins; B P Toole Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307
Authors: Wim Ceelen; Peter Smeets; Walter Backes; Nancy Van Damme; Tom Boterberg; Pieter Demetter; Isabel Bouckenooghe; Marieke De Visschere; Marc Peeters; Piet Pattyn Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-02 Impact factor: 7.038
Authors: Marco H M Janssen; Hugo J W L Aerts; Roel G J Kierkels; Walter H Backes; Michel C Ollers; Jeroen Buijsen; Philippe Lambin; Guido Lammering Journal: Radiother Oncol Date: 2010-01-18 Impact factor: 6.280
Authors: Laura Martincich; Filippo Montemurro; Giovanni De Rosa; Vincenzo Marra; Riccardo Ponzone; Stefano Cirillo; Marco Gatti; Nicoletta Biglia; Ivana Sarotto; Piero Sismondi; Daniele Regge; Massimo Aglietta Journal: Breast Cancer Res Treat Date: 2004-01 Impact factor: 4.872
Authors: I Hwang; S H Choi; C-K Park; T M Kim; S-H Park; J K Won; I H Kim; S-T Lee; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825